These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 10669645)
21. Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. Sobal G; Menzel EJ; Sinzinger H Biochem Pharmacol; 2001 Feb; 61(3):373-9. PubMed ID: 11172743 [TBL] [Abstract][Full Text] [Related]
22. Modified phosphatidylethanolamines induce different levels of cytokine expression in monocytes and dendritic cells. Simões C; Silva AC; Domingues P; Laranjeira P; Paiva A; Domingues MR Chem Phys Lipids; 2013; 175-176():57-64. PubMed ID: 23942208 [TBL] [Abstract][Full Text] [Related]
23. Phospholipase A(2) activity in non-glycated and glycated low density lipoproteins. Sakurai T; Yamamoto Y; Baba N; Nakano M Biochim Biophys Acta; 1996 May; 1301(1-2):85-9. PubMed ID: 8652655 [TBL] [Abstract][Full Text] [Related]
24. Modified phosphatidylethanolamine as the active component of oxidized low density lipoprotein promoting platelet prothrombinase activity. Zieseniss S; Zahler S; Muller I; Hermetter A; Engelmann B J Biol Chem; 2001 Jun; 276(23):19828-35. PubMed ID: 11278348 [TBL] [Abstract][Full Text] [Related]
25. Lipoprotein composition in NIDDM: effects of dietary oleic acid on the composition, oxidisability and function of low and high density lipoproteins. Dimitriadis E; Griffin M; Collins P; Johnson A; Owens D; Tomkin GH Diabetologia; 1996 Jun; 39(6):667-76. PubMed ID: 8781762 [TBL] [Abstract][Full Text] [Related]
26. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Palinski W; Koschinsky T; Butler SW; Miller E; Vlassara H; Cerami A; Witztum JL Arterioscler Thromb Vasc Biol; 1995 May; 15(5):571-82. PubMed ID: 7749871 [TBL] [Abstract][Full Text] [Related]
27. Effects of ebselen and probucol on oxidative modifications of lipid and protein of low density lipoprotein induced by free radicals. Noguchi N; Gotoh N; Niki E Biochim Biophys Acta; 1994 Jul; 1213(2):176-82. PubMed ID: 8025128 [TBL] [Abstract][Full Text] [Related]
28. Bioactive products of phospholipid oxidation: isolation, identification, measurement and activities. Subbanagounder G; Watson AD; Berliner JA Free Radic Biol Med; 2000 Jun; 28(12):1751-61. PubMed ID: 10946217 [TBL] [Abstract][Full Text] [Related]
29. Oxidation of LDL: role in atherogenesis. Hoff HF; O'Neil JA Klin Wochenschr; 1991 Dec; 69(21-23):1032-8. PubMed ID: 1798276 [TBL] [Abstract][Full Text] [Related]
30. Susceptibility of LDL and its subfractions to glycation. Soran H; Durrington PN Curr Opin Lipidol; 2011 Aug; 22(4):254-61. PubMed ID: 21734572 [TBL] [Abstract][Full Text] [Related]
31. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Jenkins AJ; Klein RL; Chassereau CN; Hermayer KL; Lopes-Virella MF Diabetes; 1996 Jun; 45(6):762-7. PubMed ID: 8635650 [TBL] [Abstract][Full Text] [Related]
32. Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins. Brown BE; Mahroof FM; Cook NL; van Reyk DM; Davies MJ Diabetologia; 2006 Apr; 49(4):775-83. PubMed ID: 16465512 [TBL] [Abstract][Full Text] [Related]
33. Glyc-oxidized LDL impair endothelial function more potently than oxidized LDL: role of enhanced oxidative stress. Galle J; Schneider R; Winner B; Lehmann-Bodem C; Schinzel R; Münch G; Conzelmann E; Wanner C Atherosclerosis; 1998 May; 138(1):65-77. PubMed ID: 9678772 [TBL] [Abstract][Full Text] [Related]
35. Effects of glucose and alpha-tocopherol on low-density lipoprotein oxidation and glycation. Chang CJ; Hsieh RH; Wang HF; Chin MY; Huang SY Ann N Y Acad Sci; 2005 May; 1042():294-302. PubMed ID: 15965075 [TBL] [Abstract][Full Text] [Related]
36. A comparative study of cultured smooth muscle cell proliferation and injury, utilizing glycated low density lipoproteins with slight oxidation, auto-oxidation, or extensive oxidation. Taguchi S; Oinuma T; Yamada T J Atheroscler Thromb; 2000; 7(3):132-7. PubMed ID: 11480453 [TBL] [Abstract][Full Text] [Related]
37. Characterization of cholesterol oxidation products formed by oxidative modification of low density lipoprotein. Chang YH; Abdalla DS; Sevanian A Free Radic Biol Med; 1997; 23(2):202-14. PubMed ID: 9199882 [TBL] [Abstract][Full Text] [Related]
38. Plasma thiols inhibit hemin-dependent oxidation of human low-density lipoprotein. Lynch SM; Campione AL; Moore MK Biochim Biophys Acta; 2000 May; 1485(1):11-22. PubMed ID: 10802245 [TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Sakata N; Imanaga Y; Meng J; Tachikawa Y; Takebayashi S; Nagai R; Horiuchi S; Itabe H; Takano T Atherosclerosis; 1998 Nov; 141(1):61-75. PubMed ID: 9863539 [TBL] [Abstract][Full Text] [Related]
40. Glycation and oxidation of human low density lipoproteins reduces heparin binding and modifies charge. Gugliucci Creriche A; Stahl AJ Scand J Clin Lab Invest; 1993 Apr; 53(2):125-32. PubMed ID: 8469911 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]